GEN Exclusives

More »

GEN News Highlights

More »
Oct 8, 2008

Cenomed Licenses TorreyPines' Compounds for Chemical Defense Settings

  • Cenomed BioSciences has acquired rights to three compounds from TorreyPines Therapeutics for chemical defense and counterterrorism defense: phenserine, Posiphen™, and bisnorcymcerine. TorreyPines will receive milestone and royalty payments.

    The company plans to prepare these compounds to prevent toxicity following exposure to chemical organophosphorus nerve agents including the chemical warfare agents sarin, soman, tabun, and VX. The candidates have the potential to restore inactivated muscle cells and neural cells throughout the body, according to the companies.

    Phenserine and Posiphen have reportedly been proven safe and well tolerated following oral administration in clinical trials, while bisnorcymcerine has completed preclinical evaluation.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Dietary Confusion

Do you think that the recent backpedaling on "heart healthy" practices, and other conflicting studies that claim coffee either causes or prevents cancer, confuse the public more than actually help them make informed choices about their diets?

More »